Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.
Novo Nordisk is under pressure over US drug prices as CEO Lars Fruergaard Jørgensen prepares to testify before the Senate ...
The current state of weight-loss treatments is about to shift with the forthcoming availability of GLP-1 drugs in the ...
The move to self-administration with a syringe and needle, just like how insulin is often taken for diabetes, means a whole ...
At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...
Pharmacist Mark Mikhael has lost 50 pounds over the past 12 months. He no longer has diabetes and finds himself “at my ideal ...
Model Lottie Moss is speaking out against the use of diabetes medication for weight loss after she allegedly overdosed on ...
It is believed that Rybelsus is great for Weight Loss Here are some effective economic and safe OTC Rybelsus Alternative ...
HealthDay on MSN7d
Will Ozempic and Wegovy Soon Be Offered as Once-a-Month Injections?A new study shows that a slow-release form of semaglutide could enable people using Wegovy or Ozempic to switch from weekly to once-a-month injections. The new formulation encases semaglutide in a ...
Shares in Novo Nordisk rose by about 2% on Wednesday, driven by positive data from its new obesity drug, amycretin, which ...
On the night of July 14, Kyle Samuels-Robey left his room at Norristown State Hospital, walked to the nurses station — and, ...
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback